Krsnaa Diagnostics Limited has informed the Exchange regarding Board meeting held on August 11, 2025.
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.9 pts less than Nifty Microcap 250 and 8.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krsnaa Diagnostics reported its Q1 FY26 (quarter ended June 30, 2025) results. On a standalone basis, revenue from operations rose to ₹1,756.15 million from ₹1,631.63 million year-on-year (up ~7.6%), while profit after tax increased to ₹195.62 million from ₹181.81 million (up ~7.6%), with EPS at ₹6.10. On a consolidated basis, revenue grew to ₹1,929.78 million from ₹1,702.32 million (up ~13.4%) and PAT rose to ₹205.20 million from ₹179.21 million (up ~14.5%), with EPS of ₹6.35. The Board fixed September 25, 2025 as the date for the 15th AGM and recommended a final dividend of ₹2.75 per share for FY25, with September 12, 2025 as the record date. The Board also approved continuation of Director Mr. Chetan Desai post age 75, subject to shareholder approval. The auditor (MSKA & Associates) issued an unqualified review report but highlighted an income tax demand of ₹513.86 million arising from past search and seizure proceedings, against which the company has paid ₹102.77 million under protest and filed appeals; management believes the demand is not tenable.
Modest single-digit revenue and profit growth on a standalone basis, with stronger double-digit growth at the consolidated level. The ₹513.86 million tax dispute is a key overhang—though management is contesting it, an adverse outcome could be material. The declared final dividend of ₹2.75 per share offers a small income cushion to shareholders.